Laval, Canada

Steve Labbe

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 3.2

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2015-2021

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Steve Labbe - A Pioneer of Innovation in Laval, CA

Introduction: Steve Labbe is a renowned inventor based in Laval, CA, whose relentless pursuit of innovation and commitment to pushing the boundaries of what is possible have made him a true pioneer in the world of technology. With a total of 8 patents to his name, his contributions continue to inspire the next generation of inventors and innovators.

Latest Patents: Steve Labbe's latest patents include fusion proteins and combination vaccines comprising Protein E and Pilin A. These patents focus on treating chronic hepatitis B infection in humans and highlight his expertise in developing novel immunogenic compositions and vaccines for therapeutic purposes.

Career Highlights: Steve Labbe currently works at GlaxoSmithKline Biologicals SA, a leading pharmaceutical company known for its groundbreaking research in biotechnology. His role at the company allows him to further explore his innovative ideas and bring them to life through patented inventions like Fusion proteins and combination vaccines comprising Protein E and Pilin A.

Collaborations: Throughout his career, Steve Labbe has collaborated with esteemed colleagues such as Jan Poolman and Normand Blais. These collaborations have not only enhanced his creative process but have also resulted in the development of cutting-edge technologies that have the potential to revolutionize the healthcare industry.

Conclusion: In conclusion, Steve Labbe's dedication to innovation, paired with his exceptional problem-solving skills and drive to make a positive impact, solidify his position as a true trailblazer in the field of technology. His work serves as a testament to the power of perseverance and creativity in shaping a better future for generations to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…